sybx-10q_20190930.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission File No. 001-37566

 

SYNLOGIC, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

State or other jurisdiction of

incorporation or organization)

 

26-1824804

(I.R.S. Employer

Identification No.)

 

 

 

301 Binney St., Suite 402

Cambridge, MA

(Address of principal executive offices)

 

02142

(Zip Code)

(617) 401-9975

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock

SYBX

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No   

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company,’’ and ‘‘emerging growth company’’ in Rule 12b–2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

 

As of November 5, 2019, there were 32,290,814 shares of the registrant’s common stock, par value $0.001 per share, outstanding.

 

 


FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained herein are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

 

 

the success of our research and development efforts;

 

the success of our collaboration and services arrangements with third parties;

 

the initiation, progress, timing, costs and results of clinical trials for our product candidates;

 

the time and costs involved in obtaining regulatory approvals for our product candidates;

 

the progress, timing and costs involved in developing manufacturing processes and agreements with third-party manufacturers;

 

the rate of progress and cost of our commercialization activities;

 

the expenses we incur in marketing and selling our product candidates;

 

the revenue generated by sales of our product candidates;

 

the emergence of competing or complementary technological developments;

 

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

the terms and timing of any additional collaborative, licensing or other arrangements that we may establish;

 

the acquisition of businesses, products and technologies;

 

our need to implement additional infrastructure and internal systems;

 

our need to add personnel and financial and management information systems to support our product development and potential future commercialization efforts, and to enable us to operate as a public company; and

 

other risks and uncertainties, including those listed under Part II, Item 1A. “Risk Factors”.

Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part II, Item 1A. “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

 

 


SYNLOGIC, INC.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

 

 

 

Page

 

 

 

PART I - FINANCIAL INFORMATION

 

 

 

 

 

Item 1. Financial Statements

 

 

 

 

 

Unaudited Consolidated Balance Sheets

 

1

 

 

 

Unaudited Consolidated Statements of Operations and Comprehensive Loss

 

2

 

 

 

Unaudited Consolidated Statements of Stockholders’ Equity

 

3

 

 

 

Unaudited Consolidated Statements of Cash Flows

 

4

 

 

 

Notes to Unaudited Consolidated Financial Statements

 

5

 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

18

 

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

27

 

 

 

Item 4. Controls and Procedures

 

27

 

 

 

PART II - OTHER INFORMATION

 

 

 

 

 

Item 1. Legal Proceedings

 

28

 

 

 

Item 1A. Risk Factors

 

28

 

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

55

 

 

 

Item 3. Defaults Upon Senior Securities

 

55

 

 

 

Item 4. Mine Safety Disclosures

 

55

 

 

 

Item 5. Other Information

 

55

 

 

 

Item 6. Exhibits

 

56

 

 

 

Signatures

 

57

 

 

 

 


SYNlogic, Inc. and SUBSIDIARIES

Unaudited Consolidated Balance Sheets

(In thousands, except share amounts)

 

 

 

September 30,

 

 

December 31,

 

 

 

 

2019

 

 

2018

 

 

Assets

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

27,458

 

 

$

11,252

 

 

Short-term marketable securities

 

 

92,808

 

 

 

111,477

 

 

Prepaid expenses

 

 

10,531

 

 

 

1,221

 

 

Other current assets

 

 

522

 

 

 

388

 

 

Total current assets

 

 

131,319

 

 

 

124,338

 

 

Long-term marketable securities

 

 

18,396

 

 

 

 

 

Property and equipment, net

 

 

13,289

 

 

 

14,841

 

 

Right of use asset - operating lease

 

 

17,674

 

 

 

 

 

Restricted cash

 

 

1,097

 

 

 

1,097

 

 

Prepaid research and development, net of current portion

 

 

20,570

 

 

 

 

 

Other assets

 

 

64

 

 

 

64

 

 

Total assets

 

$

202,409

 

 

$

140,340

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,351

 

 

$

2,421

 

 

Accrued expenses

 

 

4,028

 

 

 

4,993

 

 

Deferred revenue

 

 

1,775

 

 

 

268

 

 

Deferred rent

 

 

 

 

 

393

 

 

Lease liability - operating lease

 

 

1,925

 

 

 

 

 

Finance lease obligations

 

 

258

 

 

 

266

 

 

Total current liabilities

 

 

10,337

 

 

 

8,341

 

 

Long-term liabilities:

 

 

 

 

 

 

 

 

 

Deferred rent, net of current portion

 

 

 

 

 

7,691

 

 

Lease liability - operating lease, net of current portion

 

 

23,385

 

 

 

 

 

Finance lease obligations, net of current portion

 

 

20

 

 

 

210

 

 

Total long-term liabilities

 

 

23,405

 

 

 

7,901

 

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

 

Stockholders' Equity

 

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value

 

 

 

 

 

 

 

 

 

5,000,000 shares authorized, none issued and outstanding as of September 30, 2019 and December 31, 2018

 

 

 

 

 

 

 

Common stock, $0.001 par value

 

 

 

 

 

 

 

 

 

250,000,000 shares authorized as of September 30, 2019 and December 31, 2018. 32,290,814 and 25,401,479 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively.

 

 

33

 

 

 

25

 

 

Additional paid-in capital

 

 

326,860

 

 

 

243,903

 

 

Accumulated other comprehensive loss

 

 

114

 

 

 

(65

)

 

Accumulated deficit

 

 

(158,340

)

 

 

(119,765

)

 

Total stockholders' equity

 

 

168,667

 

 

 

124,098

 

 

Total liabilities and stockholders' equity

 

$

202,409

 

 

$

140,340

 

 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

1


 

Synlogic, INC. aND SUBSIDIARIES

Unaudited Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

 

 

 

For the Three Months Ended

 

 

For the Nine Months Ended

 

 

 

 

September 30, 2019

 

 

September 30, 2018

 

 

September 30, 2019

 

 

September 30, 2018

 

 

Revenue

 

$

305

 

 

$

1,801

 

 

$

993

 

 

$

2,409

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

10,564

 

 

 

9,934

 

 

 

30,651

 

 

 

29,167

 

 

General and administrative

 

 

3,879

 

 

 

3,401

 

 

 

11,272

 

 

 

11,764

 

 

Total operating expenses

 

 

14,443

 

 

 

13,335

 

 

 

41,923

 

 

 

40,931

 

 

Loss from operations

 

 

(14,138

)

 

 

(11,534

)

 

 

(40,930

)

 

 

(38,522

)

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest and investment income

 

 

857

 

 

 

797

 

 

 

2,373

 

 

 

2,059

 

 

Interest expense

 

 

(5

)

 

 

(10

)

 

 

(17

)

 

 

(36

)

 

Other expense

 

 

1

 

 

 

(1

)

 

 

(1

)

 

 

(5

)

 

Other income (expense), net

 

 

853

 

 

 

786

 

 

 

2,355

 

 

 

2,018

 

 

Net loss

 

$

(13,285

)

 

$

(10,748

)

 

$

(38,575

)

 

$

(36,504

)

 

Net loss per share attributable to common shareholders - basic and diluted

 

$

(0.39

)

 

$

(0.43

)

 

$

(1.33

)

 

$

(1.56

)

 

Weighted-average common shares used in computing net loss per share attributable to common shareholders - basic and diluted

 

 

34,213,096

 

 

 

25,208,117

 

 

 

28,956,280

 

 

 

23,415,242

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(13,285

)

 

$

(10,748

)

 

$

(38,575

)

 

$

(36,504

)

 

Net unrealized gains (losses) on marketable securities

 

 

46

 

 

 

28

 

 

 

179

 

 

 

(38

)

 

Comprehensive loss

 

$

(13,239

)

 

$

(10,720

)

 

$

(38,396

)

 

$

(36,542

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

 

2


Synlogic, INC. AND SUBSIDIARIES

Unaudited Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

 

 

 

Common stock

 

 

Additional

 

 

Other accumulated

 

 

 

 

 

 

 

 

 

 

 

$0.001 par

 

 

paid-in

 

 

comprehensive

 

 

Accumulated

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

income

 

 

deficit

 

 

equity

 

 

 

For the Three Months Ended September 30, 2019

 

Balance at June 30, 2019

 

 

31,719,719

 

 

$

32

 

 

$

325,778

 

 

$

68

 

 

$

(145,055

)

 

$

180,823

 

Issuance of restricted stock

 

 

585,600

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

Cancellation of restricted stock

 

 

(14,505

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustment to accrued common stock issuance costs

 

 

 

 

 

 

 

 

14

 

 

 

 

 

 

 

 

 

14

 

Equity-based compensation expense

 

 

 

 

 

 

 

 

1,069

 

 

 

 

 

 

 

 

 

1,069

 

Unrealized gain (loss) on securities

 

 

 

 

 

 

 

 

 

 

 

46

 

 

 

 

 

 

46

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,285

)

 

 

(13,285

)

Balance at September 30, 2019

 

 

32,290,814

 

 

$

33

 

 

$

326,860

 

 

$

114

 

 

$

(158,340

)

 

$

168,667

 

 

 

For the Three Months Ended September 30, 2018

 

Balance at June 30, 2018

 

 

25,432,849

 

 

$

25

 

 

$

241,756

 

 

$

(75

)

 

$

(97,086

)

 

$

144,620

 

Exercise of options

 

 

9,393

 

 

 

 

 

 

103

 

 

 

 

 

 

 

 

 

103

 

Cancellation of restricted stock

 

 

(1,901

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity-based compensation expense

 

 

 

 

 

 

 

 

1,031

 

 

 

 

 

 

 

 

 

1,031

 

Unrealized gain (loss) on securities

 

 

 

 

 

 

 

 

 

 

 

28

 

 

 

 

 

 

28

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,748

)

 

 

(10,748

)

Balance at September 30, 2018

 

 

25,440,341

 

 

$

25

 

 

$

242,890

 

 

$

(47

)

 

$

(107,834

)

 

$

135,034

 

 

 

For the Nine Months Ended September 30, 2019

 

Balance at December 31, 2018

 

 

25,401,479

 

 

$

25

 

 

$

243,903

 

 

$

(65

)

 

$

(119,765

)

 

$

124,098

 

Issuance of restricted stock

 

 

585,600

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock, net of issuance costs

 

 

6,340,771

 

 

 

7

 

 

 

56,990

 

 

 

 

 

 

 

 

 

56,997

 

Proceeds from pre-funded common stock warrants, net of issuance costs

 

 

 

 

 

 

 

 

22,874

 

 

 

 

 

 

 

 

 

22,874

 

Cancellation of restricted stock

 

 

(37,036

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity-based compensation expense

 

 

 

 

 

 

 

 

3,094

 

 

 

 

 

 

 

 

 

3,094

 

Unrealized gain (loss) on securities

 

 

 

 

 

 

 

 

 

 

 

179

 

 

 

 

 

 

179

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(38,575

)

 

 

(38,575

)

Balance at September 30, 2019

 

 

32,290,814

 

 

$

33

 

 

$

326,860

 

 

$

114

 

 

$

(158,340

)

 

$

168,667

 

 

 

For the Nine Months Ended September 30, 2018

 

Balance at December 31, 2017

 

 

16,272,617

 

 

$

16

 

 

$

156,685

 

 

$

(9

)

 

$

(71,654

)

 

$

85,038

 

Effect of adoption of ASU 2014-09 (ASC 606)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

324

 

 

 

324

 

Sale of common stock

 

 

9,179,500

 

 

 

9

 

 

 

82,657

 

 

 

 

 

 

 

 

 

82,666

 

Exercise of options

 

 

9,393

 

 

 

 

 

 

103

 

 

 

 

 

 

 

 

 

103

 

Cancellation of restricted stock

 

 

(21,169

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity-based compensation expense

 

 

 

 

 

 

 

 

3,445

 

 

 

 

 

 

 

 

 

3,445

 

Unrealized gain (loss) on securities

 

 

 

 

 

 

 

 

 

 

 

(38

)

 

 

 

 

 

(38

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(36,504

)

 

 

(36,504

)

Balance at September 30, 2018

 

 

25,440,341

 

 

$

25

 

 

$

242,890

 

 

$

(47

)

 

$

(107,834

)

 

$

135,034

 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

 

3


 

 

Synlogic, INC. AND SUBSIDIARIES

Unaudited Consolidated Statements of Cash Flows

(In thousands)

 

 

 

Nine Months Ended

 

 

Nine Months Ended

 

 

 

September 30, 2019

 

 

September 30, 2018

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(38,575

)

 

$

(36,504

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

2,989

 

 

 

1,789

 

Loss on disposal of property and equipment

 

 

 

 

 

2

 

Equity-based compensation expense

 

 

3,094

 

 

 

3,445

 

Accretion/amortization of investment securities

 

 

(1,177

)

 

 

(958

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

 

 

 

(2,000

)

Prepaid expenses and other current assets

 

 

(9,444

)

 

 

190

 

Accounts payable and accrued expenses

 

 

(670

)

 

 

(592

)

Deferred revenue

 

 

1,507

 

 

 

(410

)

Operating lease liability and right of use asset

 

 

(1,407

)

 

 

 

Deferred rent

 

 

 

 

 

1,364

 

Prepaid research and development, net of current portion

 

 

(20,571

)

 

 

 

Other assets

 

 

 

 

 

167

 

Net cash used in operating activities

 

 

(64,254

)

 

 

(33,507

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of marketable securities

 

 

(129,517

)

 

 

(144,594

)

Proceeds from maturity of marketable securities

 

 

131,146

 

 

 

58,730

 

Purchases of property and equipment

 

 

(842

)

 

 

(4,254

)

Net cash provided by (used in) investing activities

 

 

787

 

 

 

(90,118

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from exercise of stock options

 

 

 

 

103

 

Payments on finance lease obligations

 

 

(198

)

 

 

(330

)

Proceeds from sale of common stock, net of issuance costs

 

 

56,997

 

 

 

82,666

 

Proceeds from sale of pre-funded warrants, net of issuance costs

 

 

22,874

 

 

 

 

Net cash provided by financing activities

 

 

79,673

 

 

 

82,439

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

16,206

 

 

 

(41,186

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

12,349

 

 

 

59,537

 

Cash, cash equivalents and restricted cash at end of period

 

$

28,555

 

 

$

18,351

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing activities:

 

 

 

 

 

 

 

 

Landlord funded allowance for tenant improvements

 

$

 

 

$

1,654

 

Property and equipment purchases included in accounts payable and accrued expenses

 

$

(365

)

 

$

976

 

Assets acquired under operating lease obligation

 

$

2,714

 

 

$

 

Supplemental disclosure of non-cash financing activities:

 

 

 

 

 

 

 

 

Issuance costs included in accounts payable and accrued expenses

 

$

26

 

 

$

 

Purchase under finance lease

 

$

 

 

$

12

 

Cash paid for interest

 

$

17

 

 

$

35

 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

 

4


 

SYNLOGIC, INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

(1)

Nature of Business

Organization

Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (“Synlogic” or the “Company”), is a clinical-stage biopharmaceutical company focused on advancing its proprietary drug discovery and development platform to create Synthetic Biotic™ medicines which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer. Synthetic Biotic medicines are generated by applying the principles and tools of synthetic biology to engineer beneficial microbes to perform or deliver critical therapeutic functions. As living medicines, Synthetic Biotic medicines can be designed to sense a local disease context within a patient’s body and to respond by metabolizing a toxic substance, compensating for missing or damaged metabolic pathways in patients, or by delivering combinations of therapeutic factors. Synlogic’s goal is to lead in the discovery and development of Synthetic Biotic therapies as living medicines capable of robust and precise pathway complementation and delivery of therapeutic benefit to patients. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.

Synlogic, Inc. (“Private Synlogic” when referred to prior to the Merger (as defined below)) was founded and began operations on March 14, 2014, as TMC Therapeutics, Inc., located in Cambridge, Massachusetts. On July 15, 2014, TMC Therapeutics, Inc. changed its name to Synlogic, Inc. On July 2, 2015, the common and preferred stockholders of Private Synlogic executed the Synlogic, LLC Contribution Agreement (the “Contribution Agreement”), pursuant to which such common and preferred stockholders contributed such stockholders’ equity interests in Private Synlogic in exchange for common and preferred units in a newly formed parent company named Synlogic, LLC. In addition, Synlogic IBDCo, Inc. (“IBDCo”) was formed as a subsidiary of Synlogic, LLC (the “2015 Reorganization”). In conjunction with the 2015 Reorganization, Private Synlogic entered into a license, option and merger agreement with AbbVie S.à.r.l. (“AbbVie”), for the development of treatments for inflammatory bowel disease (“IBD”). See Note 9, AbbVie Collaboration Agreement.

In May 2017, Private Synlogic completed a reorganization (the “2017 Reorganization”) pursuant to which Synlogic, LLC merged with and into Private Synlogic, with Private Synlogic continuing as the surviving corporation.

On August 28, 2017, Synlogic, Inc., formerly known as Mirna Therapeutics, Inc. (NASDAQ: MIRN) (“Mirna”), completed its business combination with Private Synlogic pursuant to the Agreement and Plan of Merger and Reorganization, dated as of May 15, 2017, by and among Mirna, Meerkat Merger Sub, Inc. (“Merger Sub”), and Private Synlogic (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Private Synlogic, with Private Synlogic surviving as a wholly owned subsidiary of Mirna (the “Merger”). Immediately after completion of the Merger, Mirna changed its name to “Synlogic, Inc.” (NASDAQ: SYBX).

Risks and Uncertainties

At September 30, 2019, the Company had approximately $120.3 million in cash, cash equivalents, and short-term marketable securities, $18.4 million of long-term marketable securities, $1.1 million of restricted cash and an accumulated deficit of approximately $158.3 million. Since its inception through September 30, 2019, the Company has primarily financed its operations through the issuance of preferred stock, units and warrants, the sale of its common stock, the AbbVie collaboration, and cash received in the Merger. In June 2019, the Company issued to Ginkgo Bioworks, Inc. (“Ginkgo”), a privately held high-throughput synthetic biology company, 6,340,771 shares of common stock at a purchase price per share of $9.00, and pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 2,548,117 shares of common stock at an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering. The net proceeds to the Company were approximately $79.9 million. In the absence of positive cash flows from operations, the Company is highly dependent on its ability to find additional sources of funding in the form of debt or equity financing. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance of these financial statements.

As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), the regulatory approval process, market acceptance of the Company’s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company’s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates.  These efforts require significant amounts of

5


SYNLOGIC, INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements (continued)

 

additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities.  There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable.  Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales.  The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or partnerships.

(2)

Summary of Significant Accounting Policies

The significant accounting policies described in the Company’s audited financial statements as of and for the year ended December 31, 2018, and the notes thereto, which are included in the Company’s 2018 Annual Report for the year ended December 31, 2018, filed with the Securities and Exchange Commission (“SEC”) on March 12, 2019 (the “2018 Annual Report”), have had no material changes during the three and nine months ended September 30, 2019, other than our adoption of ASU 2016-02 (as defined below). The updated accounting policy and the impact of adoption are discussed in the “Recently Adopted Accounting Pronouncements” section in this note.

 

 

Basis of Presentation

The accompanying consolidated financial statements and the related disclosures as of September 30, 2019 and for the three and nine months ended September 30, 2019 and 2018 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the SEC for interim financial statements.  Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements.  These interim consolidated financial statements should be read in conjunction with the Company’s 2018 and 2017 audited consolidated financial statements and notes included in the Company’s 2018 Annual Report. The December 31, 2018 consolidated balance sheet included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and nine months ended September 30, 2019 and 2018.  The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or any other interim period or future year or period.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02 – Leases (Topic 842), which replaces the existing accounting guidance for leases.  This standard requires entities that lease assets to recognize the assets and liabilities for the rights and obligations created by those leases on the balance sheet.  The standard is effective for fiscal years and the interim periods within those fiscal years beginning after December 15, 2018.  The guidance is required to be applied by the modified retrospective transition approach and early adoption is permitted.  In July 2018, the FASB issued ASU 2018-11 Leases – Targeted Improvements, intended to ease the implementation of the new lease standard for financial statement preparers by, among other things, allowing for an additional transition method. In lieu of presenting transition requirements to comparative periods, as previously required, an entity may now elect to show a cumulative effect adjustment on the date of adoption without the requirement to recast prior period financial statements or disclosures presented in accordance with ASU 2016-02. The Company adopted the new standard using the cumulative effect adjustment transition option effective January 1, 2019, which is the initial date of application per ASU 2018-11.

The Company elected the available package of practical expedients which allows the Company to not reassess previous accounting conclusions around whether arrangements are or contain leases, the classification of our leases, and the treatment of initial direct costs. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet.

6


SYNLOGIC, INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements (continued)

 

The Company adopted ASU 2016-02: Leases (Topic 842) as of January 1, 2019. The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (ROU) assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated balance sheet.

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.

For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.

The lease term includes options to extend the lease when it is reasonably certain that option will be exercised. Leases with a term of 12 months or less are not recorded on the Company’s consolidated balance sheet.

The adoption had a material impact on the consolidated balance sheet related to the recognition of a transition adjustment on January 1, 2019 of a right-of-use asset of $15.9 million and lease liability of $24.0 million for an operating lease and the derecognition of deferred rent originally accounted for under legacy guidance. The adoption did not have a material impact on the consolidated statement of operations. The Company has designed and implemented changes to related processes, controls and disclosures. Refer to the Commitments and Contingencies footnote for further information on the adoption of this standard and the Company’s accounting for leases.

In February 2018, the FASB issued ASU 2018-02 – Income Statement – Reporting Comprehensive Income (Topic 220), which provides amended guidance on income tax accounting. The amended guidance permits the reclassification of the income tax effect on amounts recorded within other comprehensive income impacted by the Tax Cuts and Jobs Act (the “TCJA”) into retained earnings. The amended guidance is effective for periods beginning after December 15, 2018 and applies only to those amounts remaining in other comprehensive income at the date of enactment of the TCJA. The amended guidance may be adopted on either a retrospective basis or at the beginning of the period of adoption. The amended standard had an immaterial impact on the Company’s consolidated financial statements and as such the Company did not reclassify the income tax effects of the TCJA from other comprehensive income to retained earnings.

In June 2018, the FASB issued ASU 2018-07- Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year.   Early adoption is permitted, but no earlier than an entity’s adoption date of ASC 606. The standard expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. Under the amended guidance, equity-classified share-based payment awards issued to nonemployees will be measured at grant date fair value.  Upon transition, the entity is required to remeasure these nonemployee awards at fair value as of the adoption date.  The Company adopted the new guidance on January 1, 2019 which had an immaterial impact on its consolidated financial statements.  

 

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13 - Fair Value Measurement - Disclosure Framework (Topic 820). The standard modifies the disclosure requirements for fair value measurements. The standard is effective for public companies for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. Management is currently assessing the impact adoption will have on the Company, but it is not expected to have a material impact on the Company’s financial statement disclosures.

7


SYNLOGIC, INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements (continued)

 

In August 2018, the FASB issued ASU 2018-15 - Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The effective date of this pronouncement is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and early adoption is permitted. The standard can be adopted either using the prospective or retrospective transition approach. The Company is currently evaluating the impact of this standard on the Company's consolidated financial statements and disclosures.

 

In November 2018, the FASB issued ASU 2018-18 - Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of this standard on the Company’s consolidated financial statements.

 

(3)

Fair Value of Financial Instruments

The tables below present information about the Company’s assets that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2, Summary of Significant Accounting Policies, in the audited financial statements included in the Company’s 2018 Annual Report.  

The Company’s investment portfolio includes many fixed income securities that do not always trade on a daily basis.  As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations.  In addition, model processes were used to assess interest rate impact and develop prepayment scenarios.  These models take into consideration relevant credit information, perceived market movements, sector news and economic events.  The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.

At September 30, 2019 and December 31, 2018, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):

 

 

 

Fair Value Measurements at September 30, 2019

 

 

 

September 30,

 

 

Quoted Prices

in Active

Markets for

Identical

Assets

 

 

Significant

Other

Observable

Inputs

 

 

Significant

Unobservable

Inputs

 

Description

 

2019

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds (included in cash and cash equivalents)

 

$

16,691

 

 

$

16,691

 

 

$

 

 

$

 

Commercial paper (included in short-term investments)

 

 

36,205

 

 

 

 

 

 

36,205

 

 

 

 

Corporate debt securities (included short-term investments)

 

 

56,603

 

 

 

 

 

 

56,603

 

 

 

 

Corporate debt securities (included in long-term investments)

 

 

17,388

 

 

 

 

 

 

17,388

 

 

 

 

U.S. government agency securities and treasuries (included in long-term investments)

 

 

1,008

 

 

 

 

 

 

1,008

 

 

 

 

Total

 

$

127,895

 

 

$

16,691

 

 

$

111,204

 

 

$

 

8


SYNLOGIC, INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements (continued)

 

 

 

 

Fair Value Measurements at December 31, 2018

 

 

 

December 31,

 

 

Quoted Prices

in Active

Markets for

Identical

Assets

 

 

Significant

Other

Observable

Inputs

 

 

Significant

Unobservable

Inputs

 

Description

 

2018

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds (included in cash and cash equivalents)

 

$

265

 

 

$

265

 

 

$

 

 

$

 

Commercial paper (included in short-term investments)

 

 

57,453

 

 

 

 

 

 

57,453

 

 

 

 

Corporate debt securities (included in short-term investments)

 

 

50,052

 

 

 

 

 

 

50,052

 

 

 

 

U.S. government agency securities and treasuries (included in short-term investments)

 

 

3,972

 

 

 

1,987

 

 

 

1,985

 

 

 

 

Total

 

$

111,742

 

 

$

2,252

 

 

$

109,490

 

 

$

 

 

Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at September 30, 2019 and December 31, 2018 are carried at amounts that approximate fair value due to their short-term maturities. Finance lease obligations at September 30, 2019 and December 31, 2018 approximate fair value as they bear interest at a rate approximating a market interest rate.

(4)

Available-for-Sale Investments

 

The following tables summarize the available-for-sale securities held at September 30, 2019 and December 31, 2018 (in thousands):

 

September 30, 2019

 

Amortized cost

 

 

Gross unrealized

gains

 

 

Gross unrealized

losses

 

 

Fair Value

 

Commercial paper

 

$

36,175

 

 

$